<p>根据 Commerzbank Aktiengesellschaft FI 最近向 SEC 提交的 13F 文件，该公司在第四季度购买了 Royalty Pharma PLC（NASDAQ:RPRX - 免费报告）的新头寸。该公司购买了 25,417 股生物制药公司的股票，价值约为 982,000 美元。</p>
<p>获取 <strong>Royalty Pharma</strong> 警报：</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下产生现金</li>
</ul>
<p>其他几家对冲基金和机构投资者也对 RPRX 的头寸进行了调整。Capital International Investors 在第三季度将其在 Royalty Pharma 的股份增加了 24.4%。Capital International Investors 目前拥有 27,212,694 股生物制药公司的股票，价值为 960,064,000 美元，在上个季度又购买了 5,332,074 股。Dorsey Asset Management LLC 在第三季度购买了 Royalty Pharma 的新头寸，价值为 82,924,000 美元。Qube Research &amp; Technologies Ltd 在第三季度将其在 Royalty Pharma 的股份增加了 737.3%。Qube Research &amp; Technologies Ltd 目前拥有 2,481,771 股生物制药公司的股票，价值为 87,557,000 美元，在上个季度又购买了 2,185,366 股。Millennium Management LLC 在第三季度将其在 Royalty Pharma 的股份增加了 379.2%。Millennium Management LLC 目前拥有 2,235,133 股生物制药公司的股票，价值为 78,855,000 美元，在上个季度又购买了 1,768,702 股。最后，Clark Capital Management Group Inc.在第三季度购买了 Royalty Pharma 的新头寸，价值为 61,805,000 美元。目前 54.35% 的股票由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几家研究公司最近对 RPRX 发布了报告。高盛集团在 2 月 12 日的研究报告中重申了对 Royalty Pharma 的 “买入” 评级。Weiss Ratings 在 5 月 1 日的报告中将 Royalty Pharma 的评级从 “买入（b-）” 上调至 “买入（b）”。花旗集团在 5 月 7 日的报告中将 Royalty Pharma 的目标价从 50.00 美元上调至 66.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 4 月 10 日的报告中将 Royalty Pharma 的目标价从 61.00 美元上调至 63.00 美元，并给予该股票 “增持” 评级。最后，瑞银集团在 4 月 21 日的报告中将 Royalty Pharma 的目标价从 51.00 美元上调至 57.00 美元，并给予该股票 “买入” 评级。根据 MarketBeat.com 的数据，七位投资分析师对该股票给予了 “买入” 评级，该股票的共识评级为 “买入”，共识目标价为 53.71 美元。</p>
<ul>
<li>1 项试验，2 个特许经营：Zenas 股票因里程碑数据而上涨</li>
</ul>
<p><strong>获取我们关于 Royalty Pharma 的最新研究报告</strong></p>
<h2>内部活动</h2>
<p>在其他新闻中，董事 Gregory Norden 在 5 月 14 日的交易中出售了 3,045 股公司的股票。股票以平均价格 53.00 美元出售，总价值为 161,385.00 美元。出售后，该董事直接持有 191,803 股公司股票，价值为 10,165,559 美元。此次交易使其持股比例减少了 1.56%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席财务官 Terrance P. Coyne 在 4 月 28 日的交易中出售了 34,791 股公司的股票。股票以平均价格 49.78 美元出售，总价值为 1,731,895.98 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士共出售了 155,893 股公司股票，价值为 7,512,360 美元。公司内部人士持有 18.84% 的公司股票。</p>
<h2>Royalty Pharma 股票表现</h2>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>RPRX 股票在周五开盘价为 52.85 美元。该公司的 50 日移动平均价格为 48.31 美元，200 日移动平均价格为 43.35 美元。公司当前比率为 2.66，速动比率为 2.66，债务与股本比率为 0.86。该公司的市值为 304.3 亿美元，市盈率为 35.95，市盈率/增长比率为 1.45，贝塔值为 0.40。Royalty Pharma PLC 的 1 年最低价为 32.15 美元，1 年最高价为 53.47 美元。</p>
<p>Royalty Pharma（NASDAQ:RPRX - 获取免费报告）最后一次发布财报是在 5 月 6 日。该生物制药公司报告季度每股收益为 1.30 美元，超出市场共识预期的 1.22 美元，超出幅度为 0.08 美元。该公司季度收入为 6.31 亿美元，而分析师预期为 8.8169 亿美元。Royalty Pharma 的股本回报率为 29.25%，净利润率为 33.88%。作为一个整体，研究分析师预测 Royalty Pharma PLC 在当前年度将发布 5.05 美元的每股收益。</p>
<h2>Royalty Pharma 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 6 月 10 日支付。5 月 15 日的股东将获得 0.235 美元的分红。这相当于年化分红 0.94 美元，分红收益率为 1.8%。除息日期为 5 月 15 日。Royalty Pharma 的派息比率为 63.95%。</p>
<h2>Royalty Pharma 公司简介</h2>
<p>（免费报告）</p>
<p>Royalty Pharma plc 是一家专注于生物制药特许权使用费的金融公司，收购生物制药特许权利益，并为药物开发者和权利持有者提供非稀释性融资。该公司购买未来的特许权使用费流、里程碑支付和与已批准及晚期生物制药产品相关的其他收入权利。通过提前支付这些权利的对价，Royalty Pharma 旨在产生与多样化药物组合的商业表现相关的长期现金流。</p>
<p>公司的交易结构包括直接的特许权购买、结构性融资和根据创新公司、学术机构和投资者的需求量身定制的里程碑安排。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Royalty Pharma 更好的股票</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师喜爱的三家关键航空航天组件制造商</li>
<li>Alphabet 的 Googlebook 将 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Royalty Pharma 吗？</h2>
<p>在考虑 Royalty Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Royalty Pharma 并不在名单上。</p>
<p>虽然 Royalty Pharma 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RPRX

美国制药 ETF - iShares

<p>德意志商业银行股份公司在第四季度投资了约 98.2 万美元，购买了 25,417 股 Royalty Pharma PLC 的股票。其他机构投资者也增加了对该公司的持股。分析师对 Royalty Pharma 维持了一致的 “买入” 评级，目标价格范围在 51.00 美元到 66.00 美元之间。该股票开盘价为 52.85 美元，市值为 304.3 亿美元，市盈率为 35.95</p>

<p>Commerzbank Aktiengesellschaft FI purchased a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 25,417 shares of the biopharmaceutical company's stock, valued at approximately $982,000.</p>
<div class="lb-trans"><p>根据 Commerzbank Aktiengesellschaft FI 最近向 SEC 提交的 13F 文件，该公司在第四季度购买了 Royalty Pharma PLC（NASDAQ:RPRX - 免费报告）的新头寸。该公司购买了 25,417 股生物制药公司的股票，价值约为 982,000 美元。</p>
</div><p>Get <strong>Royalty Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Royalty Pharma</strong> 警报：</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下产生现金</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also made changes to their positions in RPRX. Capital International Investors boosted its position in shares of Royalty Pharma by 24.4% in the 3rd quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company's stock worth $960,064,000 after purchasing an additional 5,332,074 shares during the last quarter. Dorsey Asset Management LLC bought a new position in shares of Royalty Pharma in the 3rd quarter worth $82,924,000. Qube Research &amp; Technologies Ltd boosted its position in shares of Royalty Pharma by 737.3% in the 3rd quarter. Qube Research &amp; Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company's stock worth $87,557,000 after purchasing an additional 2,185,366 shares during the last quarter. Millennium Management LLC boosted its position in shares of Royalty Pharma by 379.2% in the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company's stock worth $78,855,000 after purchasing an additional 1,768,702 shares during the last quarter. Finally, Clark Capital Management Group Inc. bought a new position in shares of Royalty Pharma in the 3rd quarter worth $61,805,000. 54.35% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者也对 RPRX 的头寸进行了调整。Capital International Investors 在第三季度将其在 Royalty Pharma 的股份增加了 24.4%。Capital International Investors 目前拥有 27,212,694 股生物制药公司的股票，价值为 960,064,000 美元，在上个季度又购买了 5,332,074 股。Dorsey Asset Management LLC 在第三季度购买了 Royalty Pharma 的新头寸，价值为 82,924,000 美元。Qube Research &amp; Technologies Ltd 在第三季度将其在 Royalty Pharma 的股份增加了 737.3%。Qube Research &amp; Technologies Ltd 目前拥有 2,481,771 股生物制药公司的股票，价值为 87,557,000 美元，在上个季度又购买了 2,185,366 股。Millennium Management LLC 在第三季度将其在 Royalty Pharma 的股份增加了 379.2%。Millennium Management LLC 目前拥有 2,235,133 股生物制药公司的股票，价值为 78,855,000 美元，在上个季度又购买了 1,768,702 股。最后，Clark Capital Management Group Inc.在第三季度购买了 Royalty Pharma 的新头寸，价值为 61,805,000 美元。目前 54.35% 的股票由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research firms have recently issued reports on RPRX. The Goldman Sachs Group restated a &#34;buy&#34; rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Weiss Ratings upgraded Royalty Pharma from a &#34;buy (b-)&#34; rating to a &#34;buy (b)&#34; rating in a report on Friday, May 1st. Citigroup lifted their target price on Royalty Pharma from $50.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, May 7th. Morgan Stanley lifted their target price on Royalty Pharma from $61.00 to $63.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, April 10th. Finally, UBS Group lifted their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, April 21st. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Buy&#34; and a consensus target price of $53.71.</p>
<div class="lb-trans"><p>几家研究公司最近对 RPRX 发布了报告。高盛集团在 2 月 12 日的研究报告中重申了对 Royalty Pharma 的 “买入” 评级。Weiss Ratings 在 5 月 1 日的报告中将 Royalty Pharma 的评级从 “买入（b-）” 上调至 “买入（b）”。花旗集团在 5 月 7 日的报告中将 Royalty Pharma 的目标价从 50.00 美元上调至 66.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 4 月 10 日的报告中将 Royalty Pharma 的目标价从 61.00 美元上调至 63.00 美元，并给予该股票 “增持” 评级。最后，瑞银集团在 4 月 21 日的报告中将 Royalty Pharma 的目标价从 51.00 美元上调至 57.00 美元，并给予该股票 “买入” 评级。根据 MarketBeat.com 的数据，七位投资分析师对该股票给予了 “买入” 评级，该股票的共识评级为 “买入”，共识目标价为 53.71 美元。</p>
</div><ul>
<li>1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data</li>
</ul>
<div class="lb-trans"><ul>
<li>1 项试验，2 个特许经营：Zenas 股票因里程碑数据而上涨</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Royalty Pharma</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Royalty Pharma 的最新研究报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, Director Gregory Norden sold 3,045 shares of the business's stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the sale, the director directly owned 191,803 shares in the company, valued at $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 155,893 shares of company stock worth $7,512,360 over the last three months. Corporate insiders own 18.84% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Gregory Norden 在 5 月 14 日的交易中出售了 3,045 股公司的股票。股票以平均价格 53.00 美元出售，总价值为 161,385.00 美元。出售后，该董事直接持有 191,803 股公司股票，价值为 10,165,559 美元。此次交易使其持股比例减少了 1.56%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席财务官 Terrance P. Coyne 在 4 月 28 日的交易中出售了 34,791 股公司的股票。股票以平均价格 49.78 美元出售，总价值为 1,731,895.98 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士共出售了 155,893 股公司股票，价值为 7,512,360 美元。公司内部人士持有 18.84% 的公司股票。</p>
</div><h2>Royalty Pharma Stock Performance</h2>
<div class="lb-trans"><h2>Royalty Pharma 股票表现</h2>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>RPRX stock opened at $52.85 on Friday. The business's 50-day moving average price is $48.31 and its two-hundred day moving average price is $43.35. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The firm has a market cap of $30.43 billion, a PE ratio of 35.95, a P/E/G ratio of 1.45 and a beta of 0.40. Royalty Pharma PLC has a 1-year low of $32.15 and a 1-year high of $53.47.</p>
<div class="lb-trans"><p>RPRX 股票在周五开盘价为 52.85 美元。该公司的 50 日移动平均价格为 48.31 美元，200 日移动平均价格为 43.35 美元。公司当前比率为 2.66，速动比率为 2.66，债务与股本比率为 0.86。该公司的市值为 304.3 亿美元，市盈率为 35.95，市盈率/增长比率为 1.45，贝塔值为 0.40。Royalty Pharma PLC 的 1 年最低价为 32.15 美元，1 年最高价为 53.47 美元。</p>
</div><p>Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. The firm had revenue of $631.00 million for the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. As a group, research analysts forecast that Royalty Pharma PLC will post 5.05 earnings per share for the current year.</p>
<div class="lb-trans"><p>Royalty Pharma（NASDAQ:RPRX - 获取免费报告）最后一次发布财报是在 5 月 6 日。该生物制药公司报告季度每股收益为 1.30 美元，超出市场共识预期的 1.22 美元，超出幅度为 0.08 美元。该公司季度收入为 6.31 亿美元，而分析师预期为 8.8169 亿美元。Royalty Pharma 的股本回报率为 29.25%，净利润率为 33.88%。作为一个整体，研究分析师预测 Royalty Pharma PLC 在当前年度将发布 5.05 美元的每股收益。</p>
</div><h2>Royalty Pharma Announces Dividend</h2>
<div class="lb-trans"><h2>Royalty Pharma 宣布分红</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma's payout ratio is 63.95%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 6 月 10 日支付。5 月 15 日的股东将获得 0.235 美元的分红。这相当于年化分红 0.94 美元，分红收益率为 1.8%。除息日期为 5 月 15 日。Royalty Pharma 的派息比率为 63.95%。</p>
</div><h2>Royalty Pharma Company Profile</h2>
<div class="lb-trans"><h2>Royalty Pharma 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.</p>
<div class="lb-trans"><p>Royalty Pharma plc 是一家专注于生物制药特许权使用费的金融公司，收购生物制药特许权利益，并为药物开发者和权利持有者提供非稀释性融资。该公司购买未来的特许权使用费流、里程碑支付和与已批准及晚期生物制药产品相关的其他收入权利。通过提前支付这些权利的对价，Royalty Pharma 旨在产生与多样化药物组合的商业表现相关的长期现金流。</p>
</div><p>The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.</p>
<div class="lb-trans"><p>公司的交易结构包括直接的特许权购买、结构性融资和根据创新公司、学术机构和投资者的需求量身定制的里程碑安排。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Royalty Pharma</li>
<li>3 Stocks to Own If Gas Prices Keep Rising</li>
<li>3 Crucial Aerospace Component Makers That Analysts Love</li>
<li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li>
<li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Royalty Pharma 更好的股票</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师喜爱的三家关键航空航天组件制造商</li>
<li>Alphabet 的 Googlebook 将 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RPRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Royalty Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Royalty Pharma 吗？</h2>
</div><p>Before you consider Royalty Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Royalty Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Royalty Pharma 并不在名单上。</p>
</div><p>While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Royalty Pharma 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX

Market Beat

Royalty Pharma PLC - CL

Commerzbank AG

高盛

花旗

摩根士丹利

瑞银集团

Zenas Biopharma

GS Hldg R

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

德国商业银行股份公司 FI 投资 98.2 万美元于 Royalty Pharma PLC $RPRX